Company intelligence / Profile preview

CyberAtlas

Boston, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

CyberAtlas Therapeutics is a biotechnology company focused on developing first-in-class monoclonal antibodies for the treatment of metabolic and inflammatory diseases. The company's core technology targets extracellular fatty acid-binding protein 4 (FABP4), a hormone-like protein linked to insulin resistance, diabetes, and cardiovascular issues. Founded on pioneering research from the Harvard T.H. Chan School of Public Health, CyberAtlas aims to neutralize FABP4 to restore metabolic health. In 2021, the company was acquired by UCB, which has since advanced the lead candidate, UCB0022, into clinical development.

Therapeutic areas: EndocrinologyCardiovascularGastroenterology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Partnerships

Harvard University

Beyond the preview

Go deeper on CyberAtlas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CyberAtlas.

Explore the full profile